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ABSTRACT 
Background: To reduce the risk for treatment-emergent adverse vents and 
increase patient compliance, clinicians frequently prescribe asuboptimal start- 
ing dose of antidepressants, with the goal of increasing the dose once the pa- 
tient has demonstrated tolerability. 
Objective: The aim of this study was to examine the tolerability and effec- 
tiveness associated with an initial week of duloxetine hydrochloride treatment 
at 30 mg QD and subsequent dose increase to 60 mg QD, compared with a start- 
ing dose of 60 mg QD. 
Methods: In this open-label study, all patients met the criteria for major 
depressive disorder (MDD) described in the American Psychiatric Association's 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. 
Patients were required to wash out from previous antidepressant medications for 
21 days, and were then randomized to receive duloxetine 30 or 60 mg QD for 
1 week. After 1 week, patients receiving duloxetine 30 mg QD had their dose 
increased to 60 mg QD. Patients returned for assessments at weeks 2, 4, 6, 8, and 
12. During the remainder of the 12-week study period, the duloxetine dose could 
be titrated based onthe degree of response from 60 mg QD (minimum) to 120 mg 
QD (maximum), with 90 mg QD as an intermediate dose. Tolerability was as- 
sessed by means of discontinuation rates, spontaneously reported adverse 
events, changes in vital signs, and laboratory tests. Effectiveness measures in- 
cluded the 17-item Hamilton Rating Scale for Depression (HAMD17) total score, 
HAMD17 core and Maier subscales, individual HAMD17 items, the Hamilton Rating 
Scale for Anxiety total score, and the Clinical Global Impression of Severity. 
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Results: One hundred thirty-seven patients were enrolled (82 women, 55 men; 
mean age, 42 years; duloxetine 30 mg QD, 67 patients; duloxetine 60 mg QD, 
70 patients). The rate of discontinuation due to adverse vents did not differ 
significantly between patients tarting duloxetine at 30 mg QD and 60 mg QD 
(13.4% vs 18.6%). The most frequently reported adverse events across both 
treatment groups were nausea, headache, dry mouth, insomnia, and diarrhea. 
In the first week of treatment, patients receiving duloxetine 30 mg QD had a sig- 
nificantly lower rate of nausea compared with patients receiving 60 mg QD 
(16.4% vs 32.9%; P = 0.03). Over the 12-week acute-treatment phase, patients 
starting duloxetine treatment at 30 mg QD had a significantly lower rate of 
nausea compared with patients initiating treatment at 60 mg QD (P = 0.047). 
Although between-group differences in the HAMD 17 total score were not statis- 
tically significant at any visit, patients tarting at 30 mg QD experienced signifi- 
cantly less improvement in HAMD17 core and Maier subscales at week 1 com- 
pared with patients tarting at 60 mg QD (core, P = 0.044; Maier, P = 0.047). After 
2 weeks of treatment, the magnitude of improvement among patients tarting at 
30 mg QD did not differ significantly from that observed in patients who started 
treatment at 60 mg QD, and there were no significant between-group differences 
in effectiveness atany subsequent visit. 
Conclusions: Results from this open-label study in patients with MDD sug- 
gest that starting duloxetine treatment at 30 mg QD for 1 week, followed by 
escalation to 60 mg QD, might reduce the risk for treatment-emergent nausea in 
these patients while producing only a transitory impact on effectiveness com- 
pared with a starting dose of 60 mg QD. (Curr TherRes Clin Exp. 2005;66:522-540) 
Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Major depressive disorder (MDD) is a common and debilitating condition. In 
the United States, MDD affects >20 million people, with a lifetime prevalence 
of approximately 16%. 1 In addition to the considerable morbidity associated 
with MDD, the risk for suicide in these patients is -20-fold that of the general 
population. 2 
Effective treatment of MDD is essential. Potential consequences of under- 
treatment include prolonged suffering, suicide, occupational impairment, and 
impairment in interpersonal nd family relationships. 3 Current guidelines rec- 
ommend that antidepressant treatment be administered at a therapeutic dose 
for at least 4 to 6 months, 4 and emphasize that the primary goal of treatment 
should be the achievement of remission (ie, the virtual absence of depressive 
symptoms, usually defined as a 17-item Hamilton Rating Scale for Depression 
[HAMD17] 5,6 total score ---7). Although MDD is a potentially chronic and recur- 
ring illness, achievement of remission of all depressive symptoms during the 
initial treatment episode might reduce the risk for future episodes. 7 
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Selective serotonin reuptake inhibitors (SSRIs) currently represent the first 
line of pharmacotherapy in the treatment of MDD. However, some adverse 
events associated with initiating SSRI or serotonin/norepinephrine reuptake 
inhibitor (SNRI) therapy continue to represent a potential barrier to effective 
treatment. For example, treatment-emergent nausea is reported at rates between 
20% and 31%. 8 Strategies designed to mitigate the risk for adverse vents might 
improve patient compliance, and play an important role in ensuring that patients 
receive effective treatment of depression. 
One strategy frequently used by antidepressant prescribers i to initiate medi- 
cations at a dose less than the recommended starting dose to minimize poten- 
tial adverse ffects experienced by the patient. If the patient olerates the initial 
dose over a period of several days, the dose is then increased into the thera- 
peutic range. However, this strategy also has some potential drawbacks for the 
patient. First, the initial period of suboptimal dosing would be expected to be 
associated with reduced efficacy. Even after the dose is increased into the thera- 
peutic range, efficacy might continue to lag behind that of patients who initi- 
ated treatment at the recommended starting dose. The second, and consider- 
ably greater, concern is that patients might not receive a dose increase, although 
this problem is seen more frequently with tricyclic antidepressants (TCAs) than 
with SSRIs or SNRIs. 9 If treatment is continued at the initial suboptimal dose, 
a degree of improvement in depressive symptoms might be expected, but the 
patient is unlikely to achieve an outcome quivalent to that associated with the 
therapeutic dose. 
Duloxetine hydrochloride is a dual reuptake inhibitor of serotonin and nor- 
epinephrine that has been shown to be tolerable and effective in the acute 
treatment of MDD. 1°-14 The recommended therapeutic dose of duloxetine is 
60 mg QD. 15 The rationale underlying this recommendation, amely that 
duloxetine 60 mg QD provides an optimal combination of efficacy and tolera- 
bility, has been discussed previously. 1G In placebo-controlled clinical trials, 
the most common adverse vent associated with duloxetine 60 mg QD dosing 
was nausea, which was reported by 38% of patients. 1°'17 Although the rate of 
discontinuation due to nausea in these studies was relatively low (0.8% at 
60 mg QD; 1.4% across a dose range of 40-120 mg/d), 17 treatment-emergent 
adverse events such as nausea might have a greater impact on patient com- 
pliance in day-to-day clinical practice, where patients are often less motivated 
to continue treatment compared with clinical trial participants. Thus, starting 
doses of medications as derived from clinical trials are sometimes higher than 
those deemed tolerable in clinical practice. Furthermore, given the hetero- 
geneity of MDD and of the patients with this condition, it is unrealistic to 
believe that a single starting dose would be best in all patients. The objective 
of the present investigation was to compare the merits of 2 initial dosing reg- 
imens for duloxetine in the treatment of MDD (30 and 60 mg QD), and to estab- 
lish whether a lower starting dose would reduce the incidence of adverse 
events uch as nausea. 
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PATIENTS AND METHODS 
Study Design 
This was an open-label, multicenter trial involving 27 investigative sites in 
the United States. This study was part of a larger study comparing treatment 
outcomes in currently untreated patients initiating duloxetine (at 30 or 60 mg QD) 
with those of patients switching from SSRI/venlafaxine to duloxetine. Com- 
parisons of treatment outcomes between switching and untreated patients are 
reported in a separate publication. 18 The present analyses focus on currently 
untreated patients initiating duloxetine treatment at 30 or 60 mg QD--patients 
in the "switching" arm were excluded. The study protocol was approved by the 
institutional review board at each site, in accordance with the principles of the 
Declaration of Helsinki and its amendments,  19 and all patients provided written 
informed consent prior to participation in any study-related procedures. 
Patients could have received previous antidepressant treatment or were 
treatment naive. Patients who had received previous treatment were required 
to wash out from antidepressant medications for a period of 21 days (30 days 
in the case of fluoxetine) and were then considered to be untreated. All patients 
then entered a 1-week screening period. At the conclusion of the screening 
period, patients meeting study criteria were randomly assigned within each 
investigative site (1:1 ratio) to receive duloxetine 30 or 60 mg QD. All patients 
were required to remain at their assigned initial duloxetine dose for a 1-week ini- 
tial treatment phase. Patients unable to tolerate duloxetine treatment during 
this period were withdrawn from the study. At the end of this initial treatment 
phase, all patients receiving 30 mg QD had their duloxetine dose increased to 
60 mg QD. During the remainder of the 12-week study period, each patient's 
duloxetine dose could be titrated based on the degree of response within a 
range from 60 mg QD (minimum) to 120 mg QD (maximum), with 90 mg QD as 
an intermediate dose. The duloxetine dose could be increased or decreased 
only at scheduled visits (weeks 2, 4, 6, 8, and 12), and could be increased by 
the investigator only if the patient's HAMD17 total score was ---7 at the scheduled 
visit. 
Patients 
Patients were adult males and females (___18 years of age) meeting criteria for 
MDD defined in the American Psychiatric Association's Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, Text Revision. 2° Patients were required 
to have a HAMD17 total score ___15 and a Clinical Global Impression of Severity 
(CGI-S) 21 score ___4 at visits 1 and 2. Exclusion criteria included a diagnosis of bi- 
polar disorder, schizophrenia, or other psychotic disorder; the presence of a pri- 
mary and current Axis II disorder; a serious medical illness; serious suicidal risk; 
treatment with fluoxetine within 30 days prior to visit 1; treatment with a mono- 
amine oxidase inhibitor within 14 days prior to visit 1; lack of response of the 
current episode to 2 or more adequate courses of ant idepressant treatment at 
a clinically appropriate dose for a minimum of 4 weeks, or treatment-refractory 
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depression; any anxiety disorder as a primary diagnosis within the previous 
6 months; a history of substance dependence within the previous 6 months; 
and/or a positive urinary drug screening result. Use of concomitant medica- 
tions with primarily central nervous ystem activity was not allowed during the 
study. The use of [3-blockers, diuretics, angiotensin-converting enzyme inhibi- 
tors, antiarrhythmics, anticoagulants, and calcium channel blockers was permit- 
ted, provided the patient had been on a stable dose for a minimum of 3 months 
prior to study enrollment. 
Tolerability Measures 
Tolerability was assessed by means of discontinuation rates, spontaneously 
reported adverse events, changes in vital signs, and laboratory tests (hematol- 
ogy, urinalysis, and clinical chemistry). Abnormal vital sign values were defined 
as follows: high supine systolic (diastolic) blood pressure (BP): ___140 (---90) mm Hg 
and ___10 mm Hg greater than baseline; low supine systolic (diastolic) BP: ---90 
(---50) mm Hg and ___10 mm Hg lower than baseline; elevated (low) heart rate: 
___100 (---50) bpm and ___10 bpm greater (less) than baseline; weight gain (loss): 
body weight increase (decrease) ---7% from baseline. A patient was considered 
to have sustained hypertension if criteria for elevated systolic or diastolic BP 
were met at 3 consecutive visits. 
Effectiveness Measures 
Effectiveness measures included the HAMD17 total score, HAMD17 subscales 
(core: items 1, 2, 3, 7, and 8; Maier: items 1, 2, 7, 8, 9, and 10; anxiety: items 10, 
11, 12, 13, 15, and 17; retardation: items 1, 7, 8, and 14; sleep: items 4, 5, and 6), 
individual HAMD17 items, the Hamilton Rating Scale for Anxiety (HAMA) 22 total 
score, and the CGI-S (all measures were assessed at each study visit). Response 
was defined a priori as a ---50% reduction from baseline in HAMD17 total score. 
Remission was defined as a HAMD17 total score ---7. 
Statistical Analysis 
All analyses were conducted on an intent-to-treat basis unless otherwise speci- 
fied. All patients who received study drug were included in tolerability analy- 
ses unless otherwise specified. Patients with at least 1 postbaseline observa- 
tion were included in the effectiveness analyses. 
The primary outcome of the larger study was a comparison of stabilized 
doses for switching versus untreated patients. Using ¢x = 0.05, and assuming 
that 50% of currently untreated patients tabilized at duloxetine 60 mg QD, com- 
pared with 30% in switch patients, the study was estimated to have 86% power 
for the primary end point. For the present investigation, with -70 patients per 
arm, power to detect a difference between true rates of 20% versus 40% was 
68%, and power to detect a difference in true rates of 10% versus 20% was 30%. 
Therefore, this investigation was underpowered to detect clinically important 
differences in common adverse events between the 30 and 60 mg groups, and 
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did not have adequate power to detect between-group differences in rare events 
such as discontinuation due to adverse events and effectiveness. 
Baseline scores on HAMD17 , HAMA, and CGI-S were compared using a 1-way 
analysis of variance (ANOVA). Patient demographic characteristics were compared 
using the ANOVA model for continuous outcomes (age) and with the Fisher 
exact test for comparing percentages of categorical outcomes (sex, race). 
Longitudinal changes in effectiveness outcomes were assessed using a likelihood- 
based, mixed-effects model, repeated-measures approach. The model included 
the fixed categorical effects of group and investigator. Time of assessment was 
modeled as a continuous effect by including linear and quadratic terms for days 
on treatment, as well as the interaction of the linear and quadratic terms with 
group. Time was included as a continuous effect because the visit intervals had 
more flexibility than often seen in acute phase trials. Thus, fitting time as con- 
tinuous accounted for the unequal visit timing. Baseline severity was also includ- 
ed as a continuous covariate. Within-patient errors were modeled using an un- 
structured covariance matrix. The Kenward-Roger method was used to estimate 
denominator degrees of freedom. 
Mean changes from baseline to last observat ion in effectiveness measures 
were compared using ANOVA with a model that includes group, investigator 
and baseline severity. Probabilities of response and remission were compared 
using the Fisher exact test. 
The incidence of serious adverse events, discontinuations due to adverse 
events, and treatment-emergent adverse vents were compared using the Fisher 
exact test. Mean changes from baseline to last observation in BP and heart rate 
were compared using ANOVA with a model that includes group, investigator, 
and baseline severity. The percentages of the patients who had abnormal val- 
ues for vital signs at end point were compared using the Fisher exact test. 
RESULTS 
Patients 
A total of 137 currently untreated patients with MDD were randomized to 
receive duloxetine 30 mg QD for the first week of treatment (67 patients), or 
duloxetine 60 mg QD during the first week (70 patients) (82 women, 55 men; 
mean age, 42 years). There were no significant between-group differences in 
baseline demographic characterist ics or psychiatric profile (Table I). 
Final Prescribed Dose 
Following the initial week of fixed dosing, patients could receive flexible dos- 
ing based on the degree of response within a range from 60 to 120 mg QD, with 
90 mg QD as an intermediate dose. Within the group starting duloxetine treat- 
ment at 30 mg QD, the proport ions of patients receiving each of these doses as 
their final dose at study end point were as follows: 60 mg QD, 21/66 (31.8%) pa- 
tients; 90 mg QD, 18/66 (27.3%); 120 mg QD, 19/66 (28.8%); and other dose 
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Table I. Baseline demographic and clinical characteristics of the study patients.* 
Duloxetine Duloxetine 
30 mg QD 60 mg QD 
Baseline Characteristic (n = 67) (n = 70) 
Age, mean (SD), y 42.3 (13.5) 42.0 (12.6) 
Age range, y 19-72 18-83 
Sex, no. (%) 
Female 38 (56.7) 44 (62.9) 
Male 29 (43.3) 26 (37.1) 
Weight, mean (SD), kg 79.5 (20.7) 82.6 (21.1) 
Race, no. (%)t 
White 59 (88.1) 59 (84.3) 
Hispanic 5 (7.5) 4 (5.7) 
Black 3 (4.5) 5 (7.1) 
East Asian 0 (0.0) 2 (2.9) 
HAMDlz total score, mean (SD) 20.9 (3.7) 20.2 (3.2) 
HAMA score, mean (SD) 16.9 (5.7) 16.8 (5.6) 
CGI-S score, mean (SD) 4.36 (0.51) 4.28 (0.52) 
VAS overall pain score, mean (SD)~ 28.2 (24.1) 25.6 (22.1) 
Atypical features, no. (%)§ 7 (10.4) 3 (4.3) 
Melancholic features, no. (%)§ 43 (64.2) 45 (64.3) 
Number of previous 
episodes, mean (median) 9 (4) 6 (4) 
Duration of current episode, 
mean (median), wk 81 (26) 64 (29) 
HAMD]7 = 17-item Hamilton Rating Scale for DepressionS; HAMA = Hamilton Rating Scale for 
Anxiety22; CGI-S = Clinical Global Impression of Severity2]; VAS = visual analog scale. 
*There were no significant between-group differences in any aspect of baseline demographic or clini- 
cal characteristics. 
tpercentages may not total 100% due to rounding. 
~Patients' rating of their overall pain at baseline, using a 100-ram VAS (0 = none to 100 = as severe as 
I can imagine). 
§The presence of melancholic or atypical features (using criteria defined in the American Psychiatric 
Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 2°) was 
determined using results from the Mini International Neuropsychiatric Interview. 23 
(0 or 30 mg QD), 8/66 (12.1%). Within the group starting duloxetine at 60 mg QD, 
the proportions of patients receiving each dose at study end point were as fol- 
lows: 60 mg QD, 15/62 (24.2%) patients; 90 mg QD, 22/62 (35.5%); 120 mg QD, 
18/62 (29.0%); other dose, 7/62 (11.3%). In comparisons between the 30 and 
60 mg QD starting groups, there were no significant differences in the propor- 
tions of patients receiving each of the doses at study end point. 
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Tolerability 
Adverse Events 
Five of 137 (3.6%) patients reported serious adverse vents during the study. 
Two of these patients tarted uloxetine at 30 mg QD, and 3 patients tarted at 
60 mg QD (3.0% and 4.3%, respectively). Events reported by patients initiating 
treatment at 30 mg QD were pneumonia nd postoperative f ver (1 patient 
each), whereas events reported by patients tarting at 60 mg QD were appen- 
dicitis; superficial thrombophlebitis; and a combination ofbacteremia, nephroli- 
thiasis, pyelonephritis, pneumonia, nd congestive heart failure (1 patient each). 
During the first week of treatment, he rates of discontinuation due to ad- 
verse events in patients receiving duloxetine 30 or 60 mg QD were 3 (4.5%) pa- 
tients and 9 (12.9%) patients, respectively; this difference was not statistical- 
ly significant. Events leading to discontinuation i  the first week in patients 
receiving duloxetine 30 mg QD were somnolence, disturbance in attention, and 
blurred vision (1 patient each). Among patients receiving duloxetine 60 mg QD, 
adverse events leading to discontinuation i the first week were nausea 
(2 patients) and vomiting, abdominal pain, somnolence, fatigue, insomnia, chok- 
ing, and balance disorder (1 patient each). Over the 12-week acute-treatment 
period, the rate of discontinuation due to adverse vents did not differ signifi- 
cantly between patients tarting duloxetine at 30 mg QD and those starting 
at 60 mg QD (9 [13.4%] vs 13 [18.6%] patients). Furthermore, the rates of dis- 
continuation due to individual adverse events did not differ significantly 
between treatment groups. The adverse vents leading to discontinuation in 
>1 patient in either treatment group were nausea nd insomnia, each of which 
led to discontinuation i  2 patients tarting duloxetine at 60 mg QD. Events 
leading to discontinuation i  1 patient in each treatment group were headache 
and somnolence. Other adverse vents reported as reasons for discontinuation 
in a single patient were abdominal pain, agitation, balance disorder, bruxism, 
choking, diarrhea, disturbance in attention, fatigue, increased heart rate, hot 
flash, rash, blurred vision, and vomiting. Discontinuation due to adverse vents 
generally occurred early in treatment, with more than two thirds of all discon- 
tinuations occurring in the first 2 weeks of treatment. 
In the first week of treatment, patients tarting duloxetine treatment at 30 mg 
QD reported a significantly ower rate of nausea compared with patients initiat- 
ing treatment a 60 mg QD (11 [16.4%] vs 23 [32.9%] patients; P= 0.03) (Table IIA). 
No other event occurred at significantly different rates in the 2 treatment 
groups during the first week of treatment (fixed dose). During the 12-week 
acute-treatment phase, the overall rate of treatment-emergent adverse vents in 
patients tarting at 30 mg QD did not differ significantly from that observed in 
patients tarting at 60 mg QD (62 [92.5%] vs 63 [90.0%] patients) (Table liB). 
The most frequently reported treatment-emergent adverse vent in patients ini- 
tiating duloxetine at 30 mg QD was headache (19 [28.4%] patients), whereas 
patients tarting at duloxetine 60 mg QD most frequently reported nausea (28 
[40.0%] patients) (Table liB). Patients tarting at 30 mg QD reported a signifi- 
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Table IIA. Incidence of treatment-emergent adverse events* during the first week of 
treatment (tolerability population). Values are no. (%) of patients. 
Duloxetine Duloxetine 
30 mg QD 60 mg QD 
Parameter (n = 67) (n = 70) P 
Patients with ->1 event 45 (67.2) 53 (75.7) 0.344 
Adverse Event 
Headache 13 (19.4) 11 (15.7) 0.655 
Dry mouth 12 (1 7.9) 10 (14.3) 0.645 
Nausea 11 (16.4) 23 (32.9) 0.03 
Diarrhea 9 (13.4) 5 (7.1) 0.267 
Insomnia 8 (11.9) 5 (7.1) 0.392 
Somnolence 7 (10.4) 4 (5.7) 0.359 
Fatigue 5 (7.5) 9 (12.9) 0.400 
Dyspepsia 5 (7.5) 3 (4.3) 0.487 
Disturbance in attention 4 (6.0) 1 (1.4) 0.202 
Dizziness 4 (6.0) 5 (7.1) 1.00 
Upper abdominal pain 4 (6.0) 0 0.055 
Decreased libido 3 (4.5) 4 (5.7) 1.00 
Hyperhidrosis 3 (4.5) 4 (5.7) 1.00 
Decreased appetite 2 (3.0) 5 (7.1) 0.442 
Vomiting 1 (1.5) 4 (5.7) 0.366 
Restlessness 0 4 (5.7) 0.120 
*Events reported by >5% of patients in either treatment group. 
cantly lower rate of nausea (16 [23.9%] vs 28 [40.0%] patients; P = 0.047) and a 
significantly higher rate of upper abdominal pain (6 [9.0%] vs 0 patients; P = 
0.012) compared with patients initiating duloxetine treatment at 60 mg QD. 
Vital Signs 
During the first week of treatment, here were no significant between-group 
differences in mean changes in vital sign measurements (Table IliA). During the 
12-week acute-treatment phase, mean changes in supine systolic and diastolic 
BP were ___2 mm Hg in patients initiating duloxetine treatment at 30 mg QD or 60 mg 
QD, with no significant differences between treatment groups (Table 11113). Pa- 
tients starting duloxetine treatment at 30 mg QD had a significantly greater 
basel ine-to-end point increase in supine heart rate compared with those initi- 
ating treatment at 60 mg QD (P = 0.01). Both treatment groups had a similar 
mean decrease in body weight. 
The incidence of abnormal vital sign values at any postbasel ine visit is pre- 
sented in Table IV. The only significant between-group difference was in the 
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Table liB. Incidence of treatment-emergent adverse events* during the acute phase 
(12 weeks) (tolerability population). Values are no. (%) of patients. 
Duloxetine Duloxetine 
30 mg QD Start 60 mg QD Start 
Parameter (n = 67) (n = 70) P 
Patients with ->1 event 62 (92.5) 63 (90.0) 0.765 
Adverse event 
Headache 19 (28.4) 19 (27.1) 1.00 
Nausea 16 (23.9) 28 (40.0) 0.047 
Dry mouth 15 (22.4) 18 (25.7) 0.693 
Insomnia 12 (17.9) 12 (1 7.1 ) 1.00 
Diarrhea 12 (17.9) 9 (12.9) 0.481 
Hyperhidrosis 10 (14.9) 10 (14.3) 1.00 
Constipation 8 (11.9) 7 (10.0) 0.789 
Somnolence 8 (11.9) 9 (12.9) 1.00 
Fatigue 7 (10.4) 13 (18.6) 0.228 
Dyspepsia 7 (10.4) 5 (7.1) 0.556 
Back pain 7 (10.4) 3 (4.3) 0.201 
*Events reported by >10% of patients in either treatment group. 
Table IliA. Changes in vital signs and weight from baseline to week 1 (first week of 
treatment). Values are mean (SD). 
Duloxetine Duloxetine 
30 mg QD 60 mg QD 
Vital Sign (n = 67) (n = 65) P 
Supine heart rate, bpm 
Supine systolic BP, mm Hg 
Supine diastolic BP, mm Hg 
Weight, kg 
0.3 (11.1) -1.7 (8.9) 0.074 
3.1 (10.5) 2.4 (9.7) 0.535 
1.2 (8.1) 0.8 (7.5) 0.949 
-0.5 (1.3) -0.6 (1.2) 0.950 
BP = blood pressure. 
incidence of high supine systolic BP: the incidence in patients tarting duloxe- 
tine at 60 mg QD was significantly higher than that observed in patients tart- 
ing duloxetine treatment at 30 mg QD (14/56 [25.0%] vs 6/58 [10.3%] patients; 
P = 0.05). The incidence of abnormal weight gain or weight loss did not differ 
significantly between the 2 treatment groups (Table IV). 
Two patients tarting duloxetine at 60 mg QD met criteria for sustained hy- 
pertension during the course of the study, whereas none of the patients tart- 
ing at duloxetine 30 mg QD met criteria for sustained hypertension. 
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Table IIIB. Changes in vital signs and weight from baseline to end point. Values are 
mean (SD). 
Duloxetine Duloxetine 
30 mg QD Start 60 mg QD Start 
Vital Sign (n = 67) (n = 65) P 
Supine heart rate, bpm 
Supine systolic BP, mm Hg* 
Supine diastolic BP, mm Hg* 
Weight, kg t 
4.5 (11.3) 1.1 (11.8) 0.01 
1.8 (12.3) 0.6 (11.6) 0.390 
0.6 (9.6) -0.6 (9.1) 0.526 
-1.0 (2.5) -0.5 (3.0) 0.168 
BP = blood pressure. 
*30 mg QD start (n = 66); 60 mg QD start (n = 65). 
t30 mg QD start (n = 65); 60 mg QD start (n = 65). 
Effectiveness 
Although the between-group differences at week 1 in HAMD17 total score, 
HAMA, and CGI-S did not achieve statistical significance, patients initiating 
duloxetine treatment at 60 mg QD showed significantly greater improvement on 
the HAMD17 core and Maier subscales at week 1 compared with patients initiat- 
ing treatment at 30 mg QD (core, P = 0.044; Maier, P = 0.047) (Table VA). From 
week 2 onward (when patients could receive flexible dosing), between-group 
differences in effectiveness measures progressively diminished (Figure 1), and 
no significant differences were observed at any subsequent visit. Baseline-to- 
end point mean changes in HAMD17 total score, HAMD17 subscales, HAMA, and 
CGI-S did not differ significantly between patients initiating duloxetine treat- 
ment at 30 or 60 mg QD (Table VB). 
Estimated probabilities of response (---50% reduction in HAMD17 total score) 
at week 1 and week 12 in patients starting duloxetine treatment at 30 mg QD 
were similar to those observed in patients initiating treatment at 60 mg QD 
(week 1:30 mg QD, 13.8%; 60 mg QD, 12.3%; week 2:30 mg QD start, 23.2%; 
60 mg QD start, 21.8%; week 12:30 mg QD start, 81.5%; 60 mg QD start, 80.4%). 
Estimated probabilities of remission (HAMD17 total score,---7) at week 12 were 
67.3% in patients tarting duloxetine treatment at 30 mg QD and 66.8% in those 
starting at 60 mg QD. 
At early visits (weeks 1 and 2), patients initiating duloxetine at 60 mg QD 
showed a similar increase (worsening) in HAMD17 item 12 score (somatic 
symptoms-gastrointestinal) compared with patients starting at 30 mg QD 
(Figure 2A). At weeks 1 and 2, patients initiating duloxetine treatment at 
60 mg QD had a significant increase (worsening) in HAMD17 item 16 (loss of 
weight) compared with patients tarting at 30 mg QD (P < 0.01) (Figure 2B). 
At subsequent visits, there were no significant between-group differences on 
HAMD17 item 16. 
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Table IV. Incidence of abnormal vital sign values and abnormal weight  at any t ime 
during the 12-week study period. Values are no. (%) of patients. 
Duloxetine Duloxetine 
Vital Sign 30 mg QD Start 60 mg QD Start P 
Supine pulse 
High* 6 (9.1) 3 (4.6) 0.492 
Low* 0 1 (1.5) 0.496 
Supine systolic BP 
High t 6 (10.3) 14 (25.0) 0.050 
Low* 1 (1.8) 0 1.00 
Supine diastolic BP 
High§ 7 (12.3) 10 (18.2) 0.438 
Low* 2 (3.6) 1 (1.8) 1.00 
Weight 
Gain II 1 (1.5) 1 (1.5) 1.00 
Los# I 5 (7.7) 3 (4.6) 0.718 
BP = blood pressure. 
*30 mg QD start (n = 66); 60 mg QD 
t30 mg QD start (n = 58); 60 mg QD 
*30 mg QD start (n = 56); 60 mg QD 
§30 mg QD start (n = 57); 60 mg QD 
ll30 mg QD start (n = 65); 60 mg QD 
start (n = 65). 
start (n = 56). 
start (n = 55). 
start (n = 55). 
start (n = 65). 
Table VA. Changes in efficacy from baseline to the end of the first week of treatment.  
Values are mean (SE).* 
Duloxetine Duloxetine 
30 mg QD 60 mg QD 
Efficacy Measure (n = 67) (n = 65) P 
HAMDlz total score -4.46 (0.59) -5.33 (0.60) 0.287 
HAMDlz subscale scores 
Core 
Maier 
Anxiety 
Retardation 
Sleep 
HAMA score 
CGI-S score 
-1.98 (0.29) -2.79 (0.29) 0.044 
-2.56 (0.34) -3.50 (0.34) 0.047 
-1.25 (0.24) -1.53 (0.24) 0.415 
-1.51 (0.26) -1.94 (0.26) 0.237 
-0.58 (0.19) -0.83 (0.19) 0.342 
-3.36 (0.59) -4.78 (0.60) 0.085 
-0.45 (0.09) -0.63 (0.1 O) 0.1 74 
HAMD17 = 17-item Hamilton Rating Scale for DepressionS; HAMA = Hamilton Rating Scale for Anxiety22; 
CGI-S = Clinical Global Impression of Severity. 21 
*Mixed-effects model for repeated measures analysis. 
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Table VB. Changes in efficacy from baseline to the end of the study (week 12). 
Values are mean (SE).* 
Duloxetine Duloxetine 
30 mg QD Start 60 mg QD Start 
Efficacy Measure (n = 67) (n = 65) P 
HAMDlz total score -1 3.8 (0.9) -13.3 (0.8) 0.648 
HAMDlz subscale scores 
Core -6.64 (0.42) -6.39 (0.39) 0.659 
Maier -7.92 (0.48) -7.58 (0.45) 0.598 
Anxiety -4.14 (0.31) -3.86 (0.28) 0.508 
Retardation -5.44 (0.36) -5.07 (0.34) 0.450 
Sleep -1.98 (0.21) -2.08 (0.20) 0.731 
HAMA score -10.2 (0.81) -10.2 (0.75) 0.958 
CGI-S score -2.39 (0.17) -2.37 (0.16) 0.942 
HAMD17 = 17-item Hamilton Rating Scale for DepressionS; HAMA = Hamilton Rating 
CGI-S = Clinical Global Impression of Severity. 21 
*Mixed-effects model for repeated measures analysis. 
Scale for Anxiety22; 
DISCUSSION 
Two initial dosing regimens of duloxetine were compared in this open-label 
study: (1) a starting dose of 30 mg QD for 1 week followed by escalation to the 
therapeutic dose of 60 mg QD and (2) starting directly at 60 mg QD. The results 
suggest hat a 30 mg QD starting dose of duloxetine during the initial week of 
treatment was associated with a significantly lower risk for nausea compared 
with a 60 mg QD starting dose. However, the magnitude of improvement in some 
measures of depressive symptoms during week 1 was significantly smaller in 
patients tarting at 30 mg QD compared with those starting at 60 mg QD (core 
subscale, P = 0.044; Maier subscale, P = 0.047). 
During the first week of treatment, a 30 mg QD dose of duloxetine produced a
similar overall rate of treatment-emergent adverse vents compared with a 60 mg 
dose (67.2% vs 75.7%). Furthermore, patients receiving 30 mg QD reported asig- 
nificantly lower rate of nausea during the first week of treatment compared with 
patients receiving 60 mg QD (16.4% vs 32.9%; P = 0.03). However, certain other 
adverse vents such as insomnia, diarrhea, and somnolence were reported at 
similar rates during the first week of treatment by patients receiving duloxetine 
30 mg QD compared with the 60 mg dose. Thus, an initial week of duloxetine 
dosing at 30 mg QD appears to be associated with a significantly lower risk of 
nausea compared with a 60 mg starting dose. It should also be noted that the 
present study focused on patients who had washed out from their previous 
antidepressant medication and were not receiving treatment at the beginning of 
the study. The incidence and pattern of adverse vents might differ in patients 
switching from another antidepressant to duloxetine. 
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Although the results of this study suggest hat a 30 mg QD starting dose of 
duloxetine appears to reduce the risk for certain treatment-emergent adverse 
events, most notably nausea, this lower starting dose might only be required in 
some proportion of patients. In most patients, initiating duloxetine treatment 
directly at the therapeutic dose of 60 mg QD is well tolerated. In 2 placebo- 
controlled studies of duloxetine using a fixed dose of 60 mg QD, in which the 
protocol allowed a dose reduction to 40 mg QD during the first 3 weeks of the study, 
11% of patients required a dose reduction for tolerability reasons. 1°,11 Similarly, 
in the acute open-label phase of a relapse-prevention study, in which the proto- 
col allowed a dose reduction from 60 to 30 mg QD during the first 4 weeks, 15% 
of patients required a dose reduction for tolerability reasons. 24 In a typical out- 
patient setting, physicians might exercise clinical judgment on a case-by-case 
basis to determine which patients could benefit from a lower starting dose. 
Results from previous studies have shown that duloxetine doses could be 
escalated rapidly. 12 In a study of the tolerability and effectiveness of duloxetine 
at 120 mg/d (administered 60 mg BID), patients received uloxetine 20 mg BID 
for 3 days, followed by 3 days at 40 mg BID, and then the final dose of 60 mg 
BID. 12 In this study, the proportion of patients discontinuing treatment due to 
adverse vents did not differ significantly between the duloxetine and placebo 
treatment groups (3.2% vs 3.2%). Results from the present study suggest that pa- 
tients initiating duloxetine treatment at 30 mg QD did not experience a substan- 
tial incidence of new-onset adverse vents on dose escalation to 60 mg QD at 
the end of week 1. For example, the incidence of nausea among patients tart- 
ing at 30 mg QD was 16.4% in the first week, compared with 23.9% for the entire 
12-week study period. 
In the initial 2 to 4 weeks of treatment, he magnitude of depressive symptom 
improvement in patients tarting duloxetine at 30 mg QD was similar to that 
observed in patients tarting at 60 mg QD; between-group difference in HAMD17 
total score, HAMA total score, or CGI-S score was not statistically significant. 
After 1 week of treatment, he mean change in HAMD17 total score in patients 
receiving duloxetine 30 mg QD was 83.7% of that observed in patients receiving 
60 mg QD. Similarly, mean changes at week i in HAMA total score and CGI-S score 
among patients receiving 30 mg QD were 70.3% and 71.4%, respectively, ofthose 
observed in patients receiving duloxetine 60 mg QD. On measures of core emo- 
tional symptoms (HAMD17 core and Maier subscales) patients tarting at 30 mg 
QD experienced significantly less improvement at week 1 compared with pa- 
tients starting at 60 mg QD (P ~ 0.05). However, following the dose escalation 
from 30 to 60 mg QD at the end of week 1, the lag in effectiveness began to 
diminish. After 4 weeks of treatment, mean changes in patients who started 
duloxetine treatment at 30 mg QD were similar to those observed in patients 
who had started at 60 mg QD. Thus, the results of this study suggest hat the 
reduction in efficacy associated with an initial week of 30 mg duloxetine dosing 
appeared to be transitory and was no longer evident within 3 weeks of a dose 
escalation to 60 mg QD. 
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Mean changes in weight and vital signs were generally similar in the 2 treat- 
ment groups. The only significant between-group difference occurred in the 
comparison of mean changes in supine heart rate from baseline to end point. 
Patients tarting duloxetine at 30 mg QD had a significantly greater increase in 
supine heart rate compared with those starting at 60 mg QD (4.5 bpm vs 1.1 bpm, 
respectively; P = 0.01). The magnitude of increase in heart rate observed in 
patients tarting treatment at 30 mg QD is not consistent with observations 
from previous studies. Analyses of pooled safety data from several placebo- 
controlled studies have revealed increases in supine heart rate among duloxetine- 
treated patients of ~2 bpm at doses up to 120 mg/d. 16 Given the atypical nature 
of the present result, and the fact that the observed increase was ~5 bpm, it is 
not considered to be a clinically relevant finding. 
The incidences of abnormal increases or decreases in weight and vital signs 
were also similar between patients receiving 30 or 60 mg starting doses. How- 
ever, during the 12-week study period, the incidence of abnormal high supine 
systolic BP was significantly higher in patients receiving a 60 mg QD starting 
dose compared with those receiving a 30 mg QD starting dose (P = 0.05). 
Furthermore, 2 patients in the 60 mg QD starting group met criteria for sus- 
tained hypertension, compared with none in the 30 mg QD group. Although 
these results appear to suggest a dose response ffect, it should be noted that 
after week 1, all patients could have their duloxetine dose titrated in a range 
from 60 to 120 mg QD. In addition, the lack of a placebo arm makes interpreta- 
tion of these results difficult. In an analysis of pooled data from placebo- 
controlled studies, the incidence of sustained hypertension among duloxetine- 
treated patients (40-120 mg/d) did not differ significantly from the rate in the 
placebo group. 16 
A number of limitations of the current study should be noted. First, this was 
an open-label study. In the absence of a placebo group, interpretation of results 
should be approached with a degree of caution. 25 For this reason, the discus- 
sion of effectiveness has been limited to a comparison of the magnitude of 
improvement in each treatment group. Furthermore, the open-label nature of 
the study could also influence the rates of reporting of adverse vents. Second, 
the study design allowed flexible dosing of duloxetine after the first week of 
treatment (in a range of 60-120 mg/d), and thus the 2 study groups were not 
receiving identical treatment after week 1. However, a flexible dosing regimen 
might provide a more naturalistic setting in which to assess treatment effects, 
and provide a more accurate reflection of results typically encountered in day- 
to-day clinical practice. Furthermore, during the first week of treatment, which 
is perhaps the most important period with regard to treatment-emergent ad- 
verse events, each treatment group received a fixed dose of duloxetine (30 or 
60 mg QD). Third, this study was powered to compare treatment outcomes in 
patients initiating duloxetine (pooled 30 and 60 mg starting groups) with those 
of patients switching from SSRI/venlafaxine to duloxetine (results from the 
switching group have been published elsewhere18). Thus, contrasts between 
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the 30 and 60 mg start ing groups might have been underpowered,  although 
these analyses were specified a priori in the protocol. Fourth, this was a 12-week 
study and therefore the results and conclusions are relevant only to the acute 
t reatment  of MDD. Finally, this is the first s tudy to closely examine a QD duloxe- 
tine dose of 30 mg. Therefore, results from this open-label investigation should 
be considered preliminary. Additional double-blind studies, involving larger 
t reatment  arms, will be required to more fully val idate our initial findings with 
regard to this dose. 
CONCLUSIONS 
The results from this open-label s tudy in patients with MDD suggest hat initiat- 
ing duloxetine dosing at 30 mg QD for 1 week, followed by escalation to 60 mg 
QD, significantly reduced the risk for nausea, while producing only a t rans i tory 
impact on effectiveness, compared with start ing at 60 mg QD. 
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